Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
Jane E RogersJonathan D MizrahiLianchun XiaoChirayu MohindrooRachna T ShroffRobert WolffGauri R VaradhacharyMilind M JavleMichael OvermanDavid R FogelmanKanwal P S RaghavShubham PantFlorencia McAllisterPublished in: Cancer medicine (2020)
Our analysis revealed safety with every two-week low dose GEM-NabP while maintaining efficacy. Patient schedule convenience should factor into metastatic incurable malignancies. We suggest the use of every two-week GEM-NabP particularly in patients desiring a modified schedule.